Please ensure Javascript is enabled for purposes of website accessibility

Balchem Just Got Even Better

By Philip Saglimbeni - Dec 23, 2013 at 10:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Balchem's two recent announcements indicate that the company is gaining momentum and remains committed to increasing shareholder value.

Since I last wrote about Balchem (BCPC 3.62%), several key developments have come to light, which only serve to strengthen the chemical manufacturer as an investment. With a significant dividend raise and an increasing presence in Canada, Balchem has positioned itself to remain one of the best high-growth investments in the chemicals industry.

Industry-leading growth
Comparing a small-cap like Balchem to an industry behemoth like Dow Chemical (DOW) is beneficial to show the true power of small-cap growth. However, to gain a better perspective of Balchem's growth, it is helpful to also analyze the company alongside peers of similar size. The following is a breakdown of the company's projected growth for 2014 compared to Dow Chemical as well as smaller competitors Innophos (IPHS) and Stepan (SCL 2.58%).

 

Balchem

Dow

Innophos

Stepan

Revenue Growth 2014

13.5%

4%

5.4%

6.8%

EPS Growth 2014

21.6%

24%

35%

23.8%

The first major takeaway from the data above is that Balchem is the only listed chemical company projected to grow revenue at a rate greater than 10% in 2014. This is impressive, considering Balchem is expected to finish fiscal 2013 having grown sales 10.7%, which indicates above-average revenue growth is the norm for the company.

Even though Balchem is expected to grow earnings per share the slowest out of all listed competitors, the results are not as disappointing as they may seem at first. Innophos and Stepan are coming off particularly bad fiscal years, as both are expected to end 2013 with a decline in earnings per share.

On the other hand, Balchem is expected to finish 2013 having grown earnings per share 12.1%. Still, Dow Chemical is the best with regard to growing earnings, as it is the only company expected to grow revenue more than 20% in both 2013 and 2014.

New announcements
The first piece of news was an announcement made by management that Balchem was increasing its annual dividend. The company raised its dividend an impressive 18%, from $0.22 to $0.26.

This increase follows in a long line of dividend raises at Balchem, as the company has now increased its dividend nine times in the last 10 years. Even more impressive is that Balchem has an annual dividend growth rate of 32.4% for the last decade.

Balchem Chairman, President, and CEO Dino Rossi explained, "This annual dividend recognizes the company's strong financial performance and its commitment to share near-term successes with our shareholders."

The second piece of news was the expansion of Balchem's partnership with Versus Animal Nutrition, a provider of animal nutrient products and related services. Versus has typically serviced consumers in Western Canadian markets but is now on track to service consumers across the whole country.

As a provider of Balchem's precision release chemicals for feed animals, including AminoShure-L, KeyShure Minerals, and ReaShure, the significant expansion of Versus' distribution means an increasing global footprint for Balchem.

The director of Balchem's ruminant business, Jonathan Griffin, explained, "This expanded alliance will give the feed industry across Canada better access to Balchem's research, technical support and advanced product technologies."

Part of a strong growth story
These two new drivers of growth for Balchem fit in well with the company's larger growth strategy. With management's stated goals to continue increasing the acceptance of the company's signature products as well as exploring new opportunities through future acquisitions and alliances, Balchem appears well on its way to delivering top-of-the-line growth in the chemicals industry. 

Philip Saglimbeni has no position in any stocks mentioned. The Motley Fool recommends Balchem. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Balchem Corporation Stock Quote
Balchem Corporation
BCPC
$134.17 (3.62%) $4.69
DuPont de Nemours, Inc. Stock Quote
DuPont de Nemours, Inc.
DOW
Stepan Company Stock Quote
Stepan Company
SCL
$113.07 (2.58%) $2.84
Innophos Holdings, Inc. Stock Quote
Innophos Holdings, Inc.
IPHS

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.